Literature DB >> 2461281

Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched controls.

R Broughton1, W Dunham, J Newman, K Lutley, P Duschesne, M Rivers.   

Abstract

Twenty-four hour ambulatory sleep-wake recordings were made in 10 untreated patients with narcolepsy-cataplexy and 10 matched controls. Nocturnal sleep of narcoleptics was similar to descriptions of laboratory based recordings and was characterized by frequent sleep onset REM periods, high variability of REM latency, increased amounts of wakefulness after sleep onset, and low sleep efficiencies. Daytime portions in narcoleptics showed greater drowsiness and sleep than in controls with significantly higher amounts of stages 1A, 1B, 3, 4 and REM, more sleep episodes longer than 1 and longer than 10 min in duration, and high intersubject variability. On average, only 1.2 daytime sleep episodes began with sleep onset REM periods. There was a strong tendency in both groups towards a long mid-afternoon sleep episode often containing slow wave sleep (SWS) and which was significantly longer in narcoleptics. The mean interval between the onset of nocturnal SWS and the main daytime SWS peak was 14.1 h for narcoleptics and 13.6 h for controls. Daytime waking portions in narcoleptics showed significantly less 'active wakefulness' than in controls. There was no correlation between MSLT measures of sleepiness and amount of daytime sleep in ambulant recordings.

Entities:  

Mesh:

Year:  1988        PMID: 2461281     DOI: 10.1016/0013-4694(88)90145-9

Source DB:  PubMed          Journal:  Electroencephalogr Clin Neurophysiol        ISSN: 0013-4694


  16 in total

Review 1.  [The neurophysiology of cataplexy].

Authors:  G Mayer
Journal:  Nervenarzt       Date:  2005-12       Impact factor: 1.214

Review 2.  Narcolepsy: immunological aspects.

Authors:  Sebastiaan Overeem; John Logan Black; Gert Jan Lammers
Journal:  Sleep Med Rev       Date:  2008-03-04       Impact factor: 11.609

Review 3.  Current and emerging options for the drug treatment of narcolepsy.

Authors:  Alberto K De la Herrán-Arita; Fabio García-García
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 4.  Methods of testing for sleepiness [corrected].

Authors:  M M Mitler; J C Miller
Journal:  Behav Med       Date:  1996       Impact factor: 3.104

5.  Drowsiness/alertness algorithm development and validation using synchronized EEG and cognitive performance to individualize a generalized model.

Authors:  Robin R Johnson; Djordje P Popovic; Richard E Olmstead; Maja Stikic; Daniel J Levendowski; Chris Berka
Journal:  Biol Psychol       Date:  2011-03-17       Impact factor: 3.251

Review 6.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

7.  Cerebrospinal fluid hypocretin 1 deficiency, overweight, and metabolic dysregulation in patients with narcolepsy.

Authors:  Mona S Heier; Tine S Jansson; Kaare M Gautvik
Journal:  J Clin Sleep Med       Date:  2011-12-15       Impact factor: 4.062

Review 8.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

9.  Narcolepsy with long sleep time: a specific entity?

Authors:  Cyrille Vernet; Isabelle Arnulf
Journal:  Sleep       Date:  2009-09       Impact factor: 5.849

10.  The familial risk and HLA susceptibility among narcolepsy patients in Hong Kong Chinese.

Authors:  Lei Chen; S Y Y Fong; Ching W Lam; Nelson L S Tang; Margaret H L Ng; Albert M Li; C K W Ho; Suk-Hang Cheng; Kin-Mang Lau; Yun Kwok Wing
Journal:  Sleep       Date:  2007-07       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.